The FGFR family as drivers and biomarkers of regorafenib response in gastric cancer. [ 2017 - 2019 ]

Research Grant

Researchers: Prof John Mariadason (Principal investigator) ,  A/Pr Niall Tebbutt ,  A/Pr Nick Pavlakis ,  Dr Michael Buchert

Brief description The drug regorafenib has recently emerged as a potential new treatment for patients with gastric (stomach) cancer. We have discovered that gastric cancer cell lines which express high levels of members of the FGFR family are highly sensitive to this drug. This project will define the potential of targeting the FGFR family in gastric cancer,the value of FGFR1-4 as markers of regorafenib response, and develop strategies for enhancing regorafenib activity in this difficult to treat disease.

Funding Amount $AUD 685,998.72

Funding Scheme Project Grants

Notes Standard Project Grant